JAK/STAT in Human Disease : A Common Axis in Immunodeficiencies and Hematologic Disorders

Lydia LAMARA MAHAMMED¹Brahim Belaid¹Lilya Meriem Berkani¹Ines Allam¹Alaa Hamidou Benmoussa¹Gharnaout Merzak²Reda Djidjik^1*

• ¹Faculty of pharmacy, University of Health Sciences, Algiers, Algeria
• ²Department of Pulmonology, Beni-Messous Teaching Hospital, Algeria ,Faculty of Medicine, University of Health Sciences, Algeria, Algiers, Algeria

The JAK-STAT signaling pathway (Janus Kinase-Signal Transducer and Activator of Transcription) is a crucial molecular cascade that regulates immune responses, cell proliferation, and hematopoiesis. Germline or somatic mutations affecting this pathway leads to a wide range of pathologies, from severe immunodeficiencies to inflammatory and autoimmune diseases, as well as hematologic malignancies. Loss-of-function mutations impair cytokine signaling and primarily result in immunodeficiency, while gain-of-function mutations cause excessive pathway activation, promoting autoimmune diseases and myeloproliferative syndromes. Advances in our understanding of the JAK-STAT pathway and its involvement in various diseases have opened new perspectives in precision medicine and targeted therapies including JAK inhibitors (JAKi), gene therapy, and hematopoietic stem cell transplantation (HSCT). A detailed understanding of specific mutations and their effects on intracellular signaling allows for the refinement of therapeutic strategies and optimization of patient management. In this review, we examined the biology of the JAK-STAT pathway, highlighted the key pathogenic mutations and their clinical consequences, and described the laboratory and diagnostic approaches used to investigate this pathway.